APRICUS BIOSCIENCES, INC. (45) | Business Finance (26)

Browse by Subcategory

Recent Contracts

Amendment No. 5 to Asset Purchase Agreement, dated April 8, 2022, by and between Seelos Corporation and Phoenixus AG (Filed With SEC on April 11, 2022)
Amendment to Convertible Promissory Note, by and between Seelos Therapeutics, Inc. and Lind Global Asset Management V, LLC, dated December 10, 2021 (Filed With SEC on March 4, 2022)
Common Stock Purchase Agreement, dated as of November 24, 2021, by and between Seelos Therapeutics, Inc. and iX Biopharma Europe Limited (Filed With SEC on November 24, 2021)
Security Agreement, dated as of November 23, 2021, by and between Seelos Therapeutics, Inc. and Lind Global Asset Management V, LLC (Filed With SEC on November 24, 2021)
Underwriting Agreement, dated as of May 20, 2021, by and between Seelos Therapeutics, Inc. and Guggenheim Securities, LLC (Filed With SEC on May 21, 2021)
Form of Warrant (Filed With SEC on September 9, 2020)
Equity Distribution Agreement, dated as of June 17, 2019, by and between Seelos Therapeutics, Inc. and Piper Jaffray & Co (Filed With SEC on June 18, 2019)
Securities Purchase Agreement, dated as of November 23, 2021, by and between Seelos Therapeutics, Inc. and Lind Global Asset Management V, LLC (Filed With SEC on November 24, 2021)
Form of Convertible Promissory Note due November 23, 2024 (Filed With SEC on November 24, 2021)
Amendment No. 4 to Asset Purchase Agreement, dated February 15, 2021, by and between Seelos Corporation and Phoenixus AG (Filed With SEC on February 18, 2021)
Underwriting Agreement, dated as of January 25, 2021, by and between Seelos Therapeutics, Inc. and BTIG, LLC (Filed With SEC on January 26, 2021)
Form of Convertible Promissory Note due December 11, 2022 (Filed With SEC on December 17, 2020)
Security Agreement, dated as of December 11, 2020, by and between Seelos Therapeutics, Inc. and Lind Global Asset Management II, LLC (Filed With SEC on December 17, 2020)
Securities Purchase Agreement, dated as of December 11, 2020, by and between Seelos Therapeutics, Inc. and Lind Global Asset Management II, LLC (Filed With SEC on December 17, 2020)
Securities Purchase Agreement, dated September 4, 2020 (Filed With SEC on September 9, 2020)
Underwriting Agreement, dated as of March 11, 2020, by and between Seelos Therapeutics, Inc. and The Benchmark Company, LLC, as representative of the underwriters named therein (Filed With SEC on March 12, 2020)
Underwriting Agreement, dated as of February 10, 2020, by and between Seelos Therapeutics, Inc. and The Benchmark Company, LLC, as representative of the underwriters named therein (Filed With SEC on February 11, 2020)
Form of Underwriting Agreement (Filed With SEC on January 30, 2020)
Stock Purchase Agreement, dated as of January 2, 2020, by and between Seelos Therapeutics, Inc. and Phoenixus AG (Filed With SEC on January 3, 2020)
Amendment No. 2 to Asset Purchase Agreement, dated as of December 31, 2018, by and between Seelos Therapeutics, Inc. and Phoenixus AG f/k/a Vyera Pharmaceuticals AG and Turing... (Filed With SEC on November 7, 2019)
Amendment No. 3 to Asset Purchase Agreement, dated October 15, 2019, by and between Seelos Therapeutics, Inc. and Phoenixus AG (Filed With SEC on October 21, 2019)
Form of Securities Purchase Agreement, dated August 23, 2019 (Filed With SEC on August 27, 2019)
Form of Warrant (Filed With SEC on August 27, 2019)
Asset Purchase Agreement, dated February 15, 2019, by and between Seelos Therapeutics, Inc. and Bioblast Pharma Ltd (Filed With SEC on February 19, 2019)
Form of Series B Warrant, issued to investors on January 31, 2019 (Filed With SEC on February 6, 2019)
Form of Series A Warrant, issued to investors on January 31, 2019 (Filed With SEC on February 6, 2019)